Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ4TJK)

Drug Name
Dutasteride Drug Info
Synonyms
Avodart; Avolve; Duagen; Dutasteride [USAN]; GG 745; GI 198745; Avidart (TN); Avodart (TN); Avodart, Dutasteride; Avolve (TN); Duagen (TN); Duprost (TN); Dutagen (TN); Dutas (TN); GG-745; GI-198745; GI-198745X; Dutasteride (JAN/USAN/INN); N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; Alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (5-alpha,17-beta)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
Indication
Disease Entry ICD 11 Status REF
Benign prostatic hyperplasia GA90 Approved [1]
Prostate adenocarcinoma Approved [2]
Prostate cancer 2C82.0 Phase 3 [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
6918296
ChEBI ID
CHEMBL1200969
CAS Number
CAS 164656-23-9
TTD Drug ID
DMQ4TJK
INTEDE Drug ID
DR0555
ACDINA Drug ID
D00221

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Finasteride DMWV3TZ Baldness, male pattern Approved [3]
Polyestradiol Phosphate DM0PMGJ Prostate cancer 2C82.0 Approved [9]
Azelaic Acid DMHVL0J Acne vulgaris ED80 Approved [10]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [11]
Epristeride DM35T1O Hirsutism ED72 Phase 3 [12]
FK-143 DMEL15U Prostate disease GA91 Phase 2 [13]
Turosteride DMW7PFS Prostate disease GA91 Phase 2 [14]
IZONSTERIDE DM3KXMG Hirsutism ED72 Phase 1/2 [15]
ONO-3805 DM1RKWV Prostate disease GA91 Discontinued in Phase 3 [16]
CS-891B DM17I8O Alopecia ED70 Discontinued in Phase 2 [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [18]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [19]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [20]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [21]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [22]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [23]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [24]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [25]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [26]
Propranolol DM79NTF Angina pectoris BA40 Approved [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [28]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [29]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [30]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [31]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [32]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [33]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [34]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [35]
Verapamil DMA7PEW Angina pectoris BA40 Approved [36]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [37]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [38]
Diazepam DM08E9O Alcohol withdrawal Approved [39]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [40]
Desogestrel DM27U4Y Contraception QA21 Approved [40]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [38]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [38]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [41]
Quercetin DM3NC4M Obesity 5B81 Approved [42]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C2 (AKR1C2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [38]
Diazepam DM08E9O Alcohol withdrawal Approved [39]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [44]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [45]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [38]
Quercetin DM3NC4M Obesity 5B81 Approved [46]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [47]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [38]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [48]
Testosterone DM7HUNW Hot flushes GA30 Approved [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C1 (AKR1C1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [50]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [38]
Diazepam DM08E9O Alcohol withdrawal Approved [39]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [51]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [38]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [38]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [52]
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [53]
Ethacrynic acid DM60QMR Edema MG29 Approved [51]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Receptor tyrosine-protein kinase erbB-2 (ERBB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trastuzumab DMZQOUX Breast cancer 2C60-2C65 Approved [54]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [55]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [56]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [57]
Gefitinib DM15F0X Colon adenocarcinoma Approved [58]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [59]
Selenium DM25CGV N. A. N. A. Approved [60]
Methotrexate DM2TEOL Anterior urethra cancer Approved [61]
Quercetin DM3NC4M Obesity 5B81 Approved [62]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [64]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [43]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [65]
Metyrapone DMI7FVQ Cushing disease 5A70 Approved [66]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [67]
Diethylstilbestrol DMN3UXQ Gonorrheal vaginitis GA02 Approved [68]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [69]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [68]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [70]
Estrone DM5T6US Acne vulgaris ED80 Approved [64]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Kallikrein-2 (KLK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [71]
Testosterone DM7HUNW Hot flushes GA30 Approved [72]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [73]
Riluzole DMECBWN Amyotrophic lateral sclerosis 8B60.0 Approved [74]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [75]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [76]
Amphotericin B DMTAJQE Acne vulgaris ED80 Approved [77]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [78]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [79]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [80]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 17-beta-hydroxysteroid dehydrogenase type 3 (HSD17B3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [81]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [82]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [83]
Testosterone DM7HUNW Hot flushes GA30 Approved [84]
Dihydrotestosterone DM3S8XC Prostate hyperplasia GA90 Phase 4 [85]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [86]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [87]
HPTE DMRPZD4 Discovery agent N.A. Investigative [88]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Affected By Son of sevenless homolog 1 (SOS1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [89]
Selenium DM25CGV N. A. N. A. Approved [60]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [90]
Quercetin DM3NC4M Obesity 5B81 Approved [46]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [91]
Acocantherin DM7JT24 Atrial fibrillation BC81.3 Approved [92]
Leflunomide DMR8ONJ Arthritis FA20 Approved [93]
Testosterone enanthate DMB6871 N. A. N. A. Approved [94]
Tubocurarine DMBZIVP Anaesthesia 9A78.6 Approved [95]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [65]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ELL-associated factor 2 (EAF2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [46]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [43]
Panobinostat DM58WKG Chronic graft versus host disease Approved [96]
Testosterone DM7HUNW Hot flushes GA30 Approved [7]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [97]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [81]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [98]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [96]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [99]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [100]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Acireductone dioxygenase (ADI1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [101]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [43]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [81]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [65]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [102]
Diethylstilbestrol DMN3UXQ Gonorrheal vaginitis GA02 Approved [103]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [76]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [104]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [105]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [105]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) TT2A0DR S5A1_HUMAN; S5A2_HUMAN; PORED_HUMAN Inhibitor [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [4]
Cytochrome P450 3A5 (CYP3A5) Main DME DEIBDNY CP3A5_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) OT6EBDHM DHB1_HUMAN Gene/Protein Processing [6]
17-beta-hydroxysteroid dehydrogenase type 3 (HSD17B3) OT45D396 DHB3_HUMAN Gene/Protein Processing [6]
Acireductone dioxygenase (ADI1) OT8IOD03 MTND_HUMAN Gene/Protein Processing [7]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [8]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Gene/Protein Processing [8]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [8]
ELL-associated factor 2 (EAF2) OTSOET5L EAF2_HUMAN Gene/Protein Processing [7]
Kallikrein-2 (KLK2) OT9RE37R KLK2_HUMAN Gene/Protein Processing [6]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Gene/Protein Processing [6]
Son of sevenless homolog 1 (SOS1) OTTCWXC3 SOS1_HUMAN Gene/Protein Processing [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7457).
2 Dutasteride FDA Label
3 The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.
4 Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
5 Product monograph: Avodart (dutasteride capsules).
6 Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
7 Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
8 Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment. J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):129-40.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32.
11 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
12 Discovery of a novel hybrid from finasteride and epristeride as 5alpha-reductase inhibitor. Bioorg Med Chem Lett. 2011 Jan 1;21(1):475-8.
13 FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol. 1995 Apr;52(4):357-63.
14 Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol. 1993 Nov;46(5):549-55.
15 Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible... Urology. 2004 Jan;63(1):114-9.
16 Significant role of 5 alpha-reductase on feedback effects of androgen in rat anterior pituitary cells demonstrated with a nonsteroidal 5 alpha-redu... J Androl. 1994 Nov-Dec;15(6):521-7.
17 The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol. 2000 Dec;10(8):593-5.
18 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
19 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
20 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
21 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
24 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
25 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
26 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
27 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
28 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
29 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
30 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
31 Drug Interactions Flockhart Table
32 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
33 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
34 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
35 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
36 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
37 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
38 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
39 Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
40 Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
41 In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
42 AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
43 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
44 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
45 A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
46 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
47 Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
48 Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
49 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
50 Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
51 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
52 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
53 Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
54 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
55 Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers (Basel). 2020 Sep 27;12(10):2774. doi: 10.3390/cancers12102774.
56 Down-regulation of HER-2 expression in human breast cancer cell HBC-4 and ZR75-1 by nitrogen-mustard-N-oxide. Kobe J Med Sci. 2007;53(4):135-42.
57 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
58 Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res. 2005 Oct 15;11(20):7480-9. doi: 10.1158/1078-0432.CCR-05-0328.
59 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
60 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
61 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
62 Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
63 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
64 Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
65 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
66 The H295R system for evaluation of endocrine-disrupting effects. Ecotoxicol Environ Saf. 2006 Nov;65(3):293-305.
67 Organotin compounds enhance 17beta-hydroxysteroid dehydrogenase type I activity in human choriocarcinoma JAr cells: potential promotion of 17beta-estradiol biosynthesis in human placenta. Biochem Pharmacol. 2006 Apr 28;71(9):1349-57.
68 Estrogenic endocrine disruptive components interfere with calcium handling and differentiation of human trophoblast cells. J Cell Biochem. 2003 Jul 1;89(4):755-70.
69 Acetaminophen Modulates the Expression of Steroidogenesis-Associated Genes and Estradiol Levels in Human Placental JEG-3 Cells. Toxicol Sci. 2021 Jan 6;179(1):44-52. doi: 10.1093/toxsci/kfaa160.
70 Decreased levels of H3K9ac and H3K27ac in the promotor region of ovarian P450 aromatase mediated low estradiol synthesis in female offspring rats induced by prenatal nicotine exposure as well as in human granulosa cells after nicotine treatment. Food Chem Toxicol. 2019 Jun;128:256-266. doi: 10.1016/j.fct.2019.03.055. Epub 2019 Apr 6.
71 Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
72 Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem. 2002 Dec 13;277(50):48366-71. doi: 10.1074/jbc.M209074200. Epub 2002 Oct 9.
73 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
74 Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells. Prostate. 2019 Feb;79(2):140-150. doi: 10.1002/pros.23719. Epub 2018 Oct 2.
75 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
76 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
77 Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
78 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
79 Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007 Jan;6(1):51-60. doi: 10.1158/1535-7163.MCT-06-0144. Epub 2007 Jan 11.
80 Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol. 2005 Jan;57(1):83-92.
81 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
82 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
83 Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell. 2004 Mar;15(3):1262-72. doi: 10.1091/mbc.e03-06-0360. Epub 2003 Dec 29.
84 17beta-hydroxysteroid dehydrogenase-3 deficiency: a rare endocrine cause of male-to-female sex reversal. Gynecol Endocrinol. 2006 Sep;22(9):488-94.
85 Androgen receptor modulation following combination exposure to brominated flame-retardants. Sci Rep. 2018 Mar 19;8(1):4843. doi: 10.1038/s41598-018-23181-0.
86 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
87 The interference effects of bisphenol A on the synthesis of steroid hormones in human ovarian granulosa cells. Environ Toxicol. 2021 Apr;36(4):665-674. doi: 10.1002/tox.23070. Epub 2020 Dec 1.
88 Effects of methoxychlor and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane on 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase-3 activities in human and rat testes. Int J Androl. 2011 Apr;34(2):138-44.
89 Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
90 Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
91 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
92 Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
93 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
94 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
95 Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
96 Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
97 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
98 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
99 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
100 Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
101 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
102 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
103 Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
104 Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
105 Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.